NEW YORK, May 29, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Antibody Partnering Terms and Agreementshttp://www.reportlinker.com/p0803164/Antibody-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical
Summary This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:Antibody-drug conjugates
Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb
Polyclonal Antibodies
Trends in antibody partnering deals
Antibody partnering agreement structure
Antibody partnering contract documents
Top antibody deals by value
Most active antibody dealmakers
DescriptionThe report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
AntibodiesAntibody-drug conjugatesMonoclonal antibodiesMurine mAbChimeric mAbHumanized mAbHuman aAbPolyclonal Antibodies
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1500 links to online copies of actual antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibody dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading antibody deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of antibody deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of antibody partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in antibody partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.
Antibody Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibody trends and structure of deals entered into by leading companies worldwide.
Antibody Partnering Terms and Agreements includes:Analysis of antibody deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life antibody deals
Access to over 1500 antibody contract documents
The leading antibody deals by value since 2007
Most active antibody dealmakers since 2007
The leading antibody partnering resources
In Antibody Partnering Terms and Agreements, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Specific antibody type
Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Antibody Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1500 antibody deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise antibody rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
BenefitsIn-depth understanding of antibody deal trends since 2007Access to headline, upfront, milestone and royalty dataAnalysis of the structure of antibody agreements with numerous real life case studiesComprehensive access to over 1500 actual antibody deals entered into by the world's biopharma companiesDetailed access to actual antibody contracts enter into by the leading fifty bigpharma companiesInsight into the terms included in a antibody agreement, together with real world clause examplesUnderstand the key deal terms companies have agreed in previous dealsUndertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary Chapter 1 – Introduction Chapter 2 – Trends in antibody dealmaking2.2. Antibody partnering over the years
2.3. Bigpharma antibody dealmaking activity
2.4. Bigpharma not active in antibody partnering
2.5. Antibody partnering by deal type
2.6. Antibody partnering by disease type
2.7. Partnering by antibody type
2.8. Average deal terms for antibody partnering
2.8.1 Antibody headline values
2.8.2 Antibody upfront payments
2.8.3 Antibody milestone payments
2.8.4 Antibody royalty rates
Chapter 3 – Leading antibody deals3.2. Top antibody deals by value
3.3. Top antibody deals involving bigpharma
Chapter 4 – Bigpharma antibody deals4.2. How to use bigpharma antibody partnering deals
4.3. Bigpharma antibody partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Stada
Takeda
Teva
UCB
Warner Chilcott
Watson
Chapter 5 – Antibody dealmaking directory5.2. Company A-Z
5.3. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
5.4. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution E
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
5.5. By therapy area
Cardiovascular
Central nervous system
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hematology
Hormonal disorders
Hospital care
Immunology
Infection
Inflammatory
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Respiratory
5.6. By antibody technology type
Antibodies
Antibody-drug conjugate
Monoclonal antibodies
Chimeric mAb
Humanized mAb
Human mAb
Murine mAb
Polyclonal antibodies
Chapter 6 – Antibody partnering resource center6.2. Antibody partnering events
6.3. Further reading on antibody dealmaking
AppendicesAppendix 2 – Example antibody partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Table of figuresFigure 2: Antibody partnering since 2007
Figure 3: Bigpharma – top 50 – antibody deals 2007 to 2011
Figure 4: Bigpharma antibody deal frequency – 2007 to 2011
Figure 5: Inactive bigpharma in antibody 2007-2011
Figure 6: Antibody partnering by deal type since 2007
Figure 7: Antibody partnering by disease type since 2007
Figure 8: Antibody partnering by oncology target since 2007
Figure 9: Antibody partnering by therapeutic antibody type since 2007
Figure 10: Antibody deals with a headline value
Figure 11: Antibody deal headline value distribution, US$million – discovery stage
Figure 12: Antibody deal headline value distribution, US$million – preclinical stage
Figure 13: Antibody deal headline value distribution, US$million – phase I stage
Figure 14: Antibody deal headline value distribution, US$million – phase II stage
Figure 15: Antibody deal headline value distribution, US$million – phase III stage
Figure 16: Antibody deal headline value distribution, US$million – regulatory stage
Figure 17: Antibody deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2007-2011
Figure 19: Antibody deals with upfront payment values
Figure 20: Antibody deal upfront payment distribution, US$million – discovery stage
Figure 21: Antibody deal upfront payment distribution, US$million – preclinical stage
Figure 22: Antibody deal upfront payment distribution, US$million – phase I stage
Figure 23: Antibody deal upfront payment distribution, US$million – phase II stage
Figure 24: Antibody deal upfront payment distribution, US$million – phase III stage
Figure 25: Antibody deal upfront payment distribution, US$million – regulatory stage
Figure 26: Antibody deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2011
Figure 28: Antibody deals with milestone payments
Figure 29: Oncology deals with royalty rates, %
Figure 30: Antibody deal royalty rate distribution, US$million – discovery stage
Figure 31: Antibody deal royalty rate distribution, US$million – preclinical stage
Figure 32: Antibody deal royalty rate distribution, US$million – phase I stage
Figure 33: Antibody deal royalty rate distribution, US$million – phase II stage
Figure 34: Antibody deal royalty rate distribution, US$million – phase III stage
Figure 35: Antibody deal royalty rate distribution, US$million – regulatory stage
Figure 36: Antibody deal royalty rate distribution, US$million – marketed stage
Figure 37: Summary median royalty rate by stage of development, 2007-2011
Figure 38: Top antibody deals by value since 2007
Figure 39: Top antibody deals signed by bigpharma value since 2007
Figure 40: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Cardiovascular)
Figure 41: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Central Nervous System)
Figure 42: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Dermatology)
Figure 43: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Gastrointestinal)
Figure 44: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Genetic disorders)
Figure 45: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Genitourinary)
Figure 46: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Hematology)
Figure 47: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Hormonal)
Figure 48: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Hospital care)
Figure 49: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Immunology)
Figure 50: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Infectives)
Figure 51: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Inflammatory)
Figure 52: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Metabolic)
Figure 53: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Musculoskeletal)
Figure 54: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Oncology)
Figure 55: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Ophthalmics)
Figure 56: Recent deals (Jan 2007 to Feb 2012) - By therapy area (Respiratory)
Figure 57: Online partnering resources
Figure 58: Forthcoming partnering events
Figure 59: Deal type definitions
Figure 60: Collaborative R&D agreement for BiTE antibodies against three undisclosed solid tumor targets
To order this report:Biopharmaceutical Industry: Antibody Partnering Terms and AgreementsCheck our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article